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Key points: 
• No evidence of a reduction in prostate cancer-specific mortality with digoxin use after 
diagnosis 
• No dose response associations were apparent.  
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Abstract 
Purpose: Preclinical studies have shown that digoxin exerts anti-cancer effects on different 
cancer cell lines including prostate cancer. A recent observational study has shown that 
digoxin use was associated with a 25% reduction in prostate cancer risk. The aim of this 
study is to investigate whether digoxin use after diagnosis of prostate cancer is associated 
with decreased prostate cancer-specific mortality.  
Methods: A cohort of 13,134  prostate cancer patients newly diagnosed from 1998 to 2009 
was identified from English cancer registries and linked to the UK Clinical Practice Research 
Datalink (to provide digoxin and other prescription records) and to the Office of National 
Statistics mortality data (to identify 2,010 prostate cancer-specific deaths). Using time-
dependent Cox regression models, unadjusted and adjusted hazard ratios (HR) and 95% 
confidence intervals (CIs) were calculated for the association between post-diagnostic 
exposure to digoxin and prostate cancer-specific mortality. 
Results: Overall, 701 (5%) prostate cancer patients used digoxin after diagnosis.  Digoxin 
use was associated with an increase in prostate cancer-specific mortality before adjustment 
(HR=1.59; 95% CI 1.32-1.91), but after adjustment for confounders, the association was 
attenuated (adjusted HR=1.13; 95% CI 0.93-1.37) and there was no evidence of a dose 
response.  
Conclusions: In this large population-based prostate cancer cohort, there was no evidence of 
a reduction in prostate cancer-specific mortality with digoxin use after diagnosis.   
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Introduction  
Preclinical studies suggest that digoxin, a cardiac glycoside, exerts anti-cancer effects on 
various types of cancer including prostate cancer 1. Digoxin was found to enhance apoptosis 
of prostate cancer cell lines through several mechanisms such as inhibition of the Na+/K+ 
pump activity leading to reductions  in the proliferation of prostate cancer cell lines 2,3. A 
recent in vitro screen of 3,817 compounds identified digoxin as the candidate with the most 
potential for use in prostate cancer treatment based upon its ability to inhibit proliferation in  
prostate cancer cell lines 4.  The researchers also conducted observational epidemiology 
showing, in the Health Professionals Follow-up Study, that digoxin users had a significant 
24% reduction in prostate cancer risk 4.  However, there have not been any epidemiological 
studies which have investigated the effect of digoxin use after prostate cancer diagnosis on 
survival.  A recent study has investigated the association between digoxin use before prostate 
cancer diagnosis and survival from prostate cancer 5, but this is a less relevant time period, as 
intervening prior to a cancer diagnosis in order to improve survival is of questionable clinical 
applicability. The aim of our population-based study was to investigate whether prostate 
cancer patients using digoxin after diagnosis had reduced prostate cancer-specific mortality. 
 
Materials and Methods 
Data source 
This study was conducted using three databases. The Clinical Practice Research Datalink 
(CPRD), the National Cancer Data Repository (NCDR) and the Office of National Statistics 
(ONS). These datasets were linked using a deterministic algorithm based upon National 
Health Service (NHS) number, gender, date of birth, and postcode.  Ethical approval for all 
observational research using the CPRD has been obtained from a multicentre research ethics 
committee. 
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Study design  
A cohort of newly diagnosed prostate cancer patients was identified on the basis of a NCDR 
recorded primary diagnosis of prostate cancer (based upon International Classification of 
Diseases (ICD)) from an English cancer registry between 1998 and 2009. Cohort members 
with a previous NCDR cancer diagnosis, apart from in situ neoplasms and non-melanoma 
skin cancers, were excluded.  Deaths were identified from the ONS with information on 
deaths up to January 2012, with prostate cancer-specific deaths defined as those with 
underlying cause of death based upon ICD codes. Patients were removed if their cancer 
diagnosis date occurred before they were registered at a CPRD practice, if their cancer 
diagnosis date occurred before the CPRD records at their General Practitioner (GP) practice 
were of research quality (up to standard), if their cancer diagnosis date occurred after the last 
date of data collection from their general practice, or if they received androgen deprivation 
therapy (ADT) more than 8 weeks prior to the date of their cancer diagnosis. Follow-up 
started one year after prostate cancer diagnosis to remove deaths in the first year after 
diagnosis.  
 
Exposure data 
Digoxin was determined from GP prescribing records. A quantity of 28 tablets was assumed 
for approximately 1% of prescriptions where quantity was missing or assumed incorrect. The 
Defined Daily Doses (DDDs) in each prescription were calculated. Digoxin use was 
investigated as a time varying covariate 6. The use of a lag is recommended 7 and in this 
study, prescriptions in the 6 months prior to death were removed by the lag as these may 
reflect end of life treatment. Dose-response analyses were conducted.  
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Covariates 
Data available from NCDR included histological grade and treatment in the six months after 
diagnosis. ADT use was determined from GP prescription records. Smoking, alcohol, and 
body mass index (BMI) were determined from the closest GP record prior to prostate cancer 
diagnosis. Comorbidities prior to diagnosis were determined prior to diagnosis from GP 
diagnosis codes using comorbidities comprising a recent adaptation of the Charlson 
comorbidity index to Read coding databases such as CPRD 8. Deprivation was based upon 
postcode of residence using the 2004 Index of Multiple Deprivation for England 9. Statin, 
metformin, angiotensin-converting-enzyme inhibitors (ACEI), spironolactone and aspirin use 
was determined from GP prescription records. 
 
Statistical analysis 
The patients were followed from one year after prostate cancer diagnosis to death, end of 
registration with their general practice, last date of data collection from their general practice 
or end of ONS mortality death registration data follow-up. In the main analysis, time-
dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% 
confidence intervals (CIs) for prostate cancer-specific death for digoxin users compared with 
non-users. Adjusted analyses were conducted including potential confounders. Further 
analyses were conducted by considering the number of digoxin prescriptions and number of 
DDDs. Analyses were repeated for all-cause mortality. Subgroup and sensitivity analyses 
were also conducted.  
 
Results 
Figure 1 shows that the final cohort included 13,134 prostate cancer patients with a mean of 5 
years of follow-up from diagnosis, in whom there were 2,010 prostate cancer-specific deaths, 
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and 1,885 deaths from other causes. Smaller proportions of digoxin users compared with non-
users were younger, and were current smokers. Digoxin users were much less likely to 
receive surgery or radiotherapy but more likely to receive hormone therapy. Digoxin users 
were more likely to have comorbidities (particularly for cerebrovascular disease, chronic 
pulmonary disease, congestive heart disease, diabetes and myocardial infarction) and use 
other medications (such as low- dose aspirin, spironolactone, statins, metformin, and ACEI). 
Other characteristics, including Gleason score and grade, were generally similar in digoxin 
users compared with non-users. 
 
The findings for prostate cancer-specific and all-cause mortality are shown in Table 1. 
Digoxin use was associated with increased prostate cancer-specific mortality before 
adjustment (HR=1.59; 95% CI 1.32-1.91) but after adjustment for confounders, the 
association was attenuated (adjusted HR=1.13; 95% CI 0.93-1.37). This attenuation was 
largely due to adjustment for age (HR adjusted for age=1.22; 95% CI 1.02-1.47) and no dose 
response associations were apparent.   
 
There was a large increase in all-cause mortality in digoxin users prior to adjustments 
(HR=2.24; 95% CI 2.00-2.51) and after adjustment for confounders, a weak association 
remained (HR=1.39; 95% CI 1.23-1.56).  This increase was most marked for cardiovascular 
deaths (adjusted HR=1.85; 95% CI 1.49-2.31), as expected, and there was only a modest 
increase in the risk of death for non-cardiovascular causes (adjusted HR=1.25; 95% CI 1.08-
1.44).  
 
In sub-group analyses, the results were little altered when the cohort was restricted to 
individuals with digoxin indications (in which the digoxin non-users are likely to be more 
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similar to the digoxin users) (adjusted HR=1.07; 95% CI 0.78-1.46), and when the cohort was 
restricted to individuals receiving ADT (adjusted HR=1.18; 95% CI 0.95-1.46). A simplified 
analysis for prostate cancer-specific mortality, based upon digoxin use in the year after 
diagnosis, also revealed little evidence of association (adjusted HR=1.20; 95% CI 0.97- 1.49). 
A further sensitivity analyses revealed a small increase in prostate cancer-mortality with 
digoxin use in the year before diagnosis (adjusted HR=1.25; 95% CI 1.03- 1.52). Finally, 
there was no evidence of a difference in cancer-specific mortality in digoxin users compared 
with non-users when the analysis was restricted to those for whom Gleason score was 
available and additionally adjusted for (adjusted HR=0.94; 95% CI 0.67-1.31).   
Discussion 
In this study, there was no evidence of reduced prostate cancer-specific mortality in prostate 
cancer patients who used digoxin. 
 
This study is the first population-based cohort to investigate digoxin use after diagnosis of 
prostate cancer and mortality. Our findings are similar to the lack of association between 
digoxin and prostate cancer-specific mortality observed in an Irish study of digoxin and 
mortality 5, but that study only investigated digoxin use prior to diagnosis of prostate cancer. 
Our findings do not support preclinical studies which suggest digoxin has anticancer 
properties 10.  Epidemiological studies have suggested reductions in prostate cancer risk in 
digoxin users 4,11, our findings suggest that any reductions in risk may not translate to 
survival possibly because different mechanisms may be involved in metastasis and tumour 
initiation.  
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The main strengths of our study include its large size and long duration of follow-up but we 
cannot rule out the possibility of a type 2 error. Although verification of cancer diagnosis and 
death facilitated using NCDR and ONS data respectively were robust, misclassification of 
prostate cancer cause of death is possible; however, methodological studies suggest that 
comparative risk estimates are unlikely to be greatly affected where misclassification is 
unlikely to be differential 12. Recall bias was eliminated by using routinely collected GP-
prescribed drug data that included detailed timing of digoxin use; nevertheless it did not 
capture hospital or hospice prescriptions. Confounding by indication, often a problem in 
pharmacoepidemiology, is unlikely to have influenced our main finding for prostate cancer-
specific mortality, but would explain the increase in all-cause mortality due largely to raised 
cardiovascular mortality in digoxin users 13. Misclassification of digoxin usage is possible 
because it is unknown whether patients fully complied with their prescriptions. However, 
most digoxin prescribing will have been captured as digoxin is not available over-the-counter 
in the UK. As with all observational studies, confounding caused by unrecorded\unavailable 
variables (such as stage) or incomplete potential confounders cannot be ruled out.  
 
Conclusion 
There was no evidence of a reduction in prostate cancer-specific mortality with digoxin use 
after diagnosis.  
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17,240 prostate cancer patients in 
NCDR* diagnosed 1998-2009 with 
available CPRD data from date of 
diagnosis 
 1,653 cancer diagnoses preceded CPRD research quality records† 
 
15,587 prostate cancer patients 
82 cancer diagnoses after last date of download of prescription data 
1,815 had < 1 year of follow-up after cancer diagnosis 
  782 died from prostate cancer within 1 year of cancer diagnosis 
  1,033 died from other cause within 1 year of cancer diagnosis 
14,949 prostate cancer patients 
 
13,134 prostate cancer patients comprising 
   2,010 prostate cancer-specific deaths, and 
   1,885 deaths from other causes 
15,505 prostate cancer patients 
556 hormone therapy preceded prostate cancer diagnosis by 8 weeks † 
Figure 1. 
* With no history of other cancers in NCDR, excluding in situ neoplasms and non-melanoma skin cancers. 
† Indicating date of diagnosis may not be correctly recorded in cancer registry. 
 
13 
 
 
 
Table 1. Association between digoxin usage after cancer diagnosis and prostate cancer-specific and all-cause 
mortality. 
Medication usage after 
diagnosis 
Cancer-
specific/ 
all-cause 
mortality 
All 
patients 
Person 
years 
Unadjusted HR 
(95%CI)  
Adjusteda HR 
(95%CI)  
Prostate cancer-specific mortality  
Number of patients [13,134]  
        
Digoxin non-user 1,890 12,433 50,736 1.00  1.00  
Digoxin user b 120 701 2,106 1.59 (1.32, 1.91)  1.13 (0.93, 1.37)  
        
Digoxin non-user 1,890 12,433 50,736 1.00  1.00  
 1 to 11 Digoxin prescriptions c 57 268 916 1.61 (1.23, 2.09)  1.15 (0.88, 1.50)  
  ≥ 12 Digoxin prescriptions c 63 433 1,190 1.57 (1.22, 2.02)  1.10 (0.85, 1.43)  
        
        
Digoxin non-user 1,890 12,433 50,736 1.00  1.00  
 1 to 365 ddds c 76 362 1,147 1.73 (1.38, 2.18)  1.17 (0.92, 1.48)  
  ≥ 365 ddds  c 44 339 959 1.38 (1.03, 1.87)  1.06 (0.78, 1.44)  
All-cause mortality  
Number of patients [13,134]  
        
Digoxin non-user 3,566 12,433 50,736 1.00  1.00  
Digoxin user b 329 701 2,106 2.24 (2.00, 2.51)  1.39 (1.23, 1.56)  
        
Digoxin non-user 3,566 12,433 50,736 1.00  1.00  
 1 to 11 Digoxin prescriptions c 135 268 916 2.06 (1.73, 2.45)  1.30 (1.09, 1.55)  
  ≥ 12 Digoxin prescriptions c 194 433 1,190 2.40 (2.07, 2.77)  1.46 (1.25, 1.70)  
        
        
Digoxin non-user 3,566 12,433 50,736 1.00  1.00  
 1 to 365 ddds c 191 362 1,147 2.34 (2.03, 2.71)  1.36 (1.17, 1.58)  
  ≥ 365 ddds  c 138 339 959 2.12 (1.78, 2.51)  1.42 (1.19, 1.70)  
        
ddds, defined daily doses. 
a Model includes year of diagnosis, age at diagnosis, surgery within 6 months, radiotherapy within 6 months, 
chemotherapy within 6 months, androgen deprivation therapy within 6 months, estrogen therapy within 6 
months, comorbidities prior to diagnosis (including cerebrovascular disease, chronic pulmonary disease, 
congestive heart disease, diabetes, diabetes with complications, myocardial infarction, peptic ulcer disease, 
peripheral vascular disease, renal disease) and other medication use (after diagnosis, as time varying covariates, 
specifically low-dose aspirin, statins, metformin, ACEI and spironolactone) and deprivation (in fifth). 
b Medication use modelled as a time varying covariate with an individual considered a non-user prior to 6 
months after first medication usage and a user after this time, excludes deaths in the year after cancer diagnosis. 
c Medication use modelled as a time varying covariate with an individual considered a non-user prior to 6 
months after first medication usage, a user of 0 to 12 prescriptions (or 365th defined daily doses) from 6 months 
after first prescription to 6 months after 12th prescription (or 365th defined daily dose) and a greater user after 
this time, excludes deaths in the year after cancer diagnosis. 
 
 
